Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells.

Hiroaki Shiraishi, Kazuhisa Ikemoto, Shin Tada, Yasuhiro Udagawa, Masatsugu Ohtsuki, Chiho Sumi-Ichinose, Kazunao Kondo, Takahide Nomura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cilostazol, a type III phosphodiesterase inhibitor, is utilized for the treatment of intermittent claudication and is considered to have the beneficial effects against the atherogenic process. In the present study, we examined the effects of cilostazol on BH(4) biosynthesis in HUVEC treated with a mixture of the pro-inflammatory cytokines IFN-γ and TNF-α. Isolated HUVECs were grown to confluence and treated with IFN-γ (300 units/mL) and TNF-α (300 units/mL) for 16 h in order to stimulate BH(4) biosynthesis. The BH(4) levels were measured by HPLC. The mRNA expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme of BH(4) biosynthesis, and GTPCH feedback regulatory protein (GFRP) were quantified by real-time PCR. The GTPCH protein expression was assessed by western blot analysis. Cilostazol significantly reduced the BH(4) levels in cytokine-stimulated HUVEC. Cilostazol produced a concomitant increase in the cAMP levels in HUVEC. Cilostazol decreased the GTPCH activity as well as the expression of GTPCH mRNA and protein. 8-bromo-cAMP (8Br-cAMP), a cell-permeable cAMP analogue, did not reproduce the effects of cilostazol. Cilostazol did not affect the cytokine-induced inhibition of GFRP mRNA expression. We conclude that cilostazol inhibited cytokine-stimulated BH(4) biosynthesis via a cAMP-independent mechanism in HUVEC. Our data indicate that cilostazol reduced GTPCH activity and did so by suppressing the GTPCH protein levels.

Original languageEnglish
Pages (from-to)312-317
Number of pages6
JournalJournal of atherosclerosis and thrombosis
Volume18
Issue number4
DOIs
Publication statusPublished - 27-04-2011

Fingerprint

GTP Cyclohydrolase
Biosynthesis
Endothelial cells
Human Umbilical Vein Endothelial Cells
Cytokines
Proteins
Messenger RNA
Feedback
8-Bromo Cyclic Adenosine Monophosphate
cilostazol
sapropterin
Intermittent Claudication
Phosphodiesterase Inhibitors
Real-Time Polymerase Chain Reaction
Western Blotting
High Pressure Liquid Chromatography
Enzymes

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Shiraishi, Hiroaki ; Ikemoto, Kazuhisa ; Tada, Shin ; Udagawa, Yasuhiro ; Ohtsuki, Masatsugu ; Sumi-Ichinose, Chiho ; Kondo, Kazunao ; Nomura, Takahide. / Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells. In: Journal of atherosclerosis and thrombosis. 2011 ; Vol. 18, No. 4. pp. 312-317.
@article{85e46c8b050a42ff8605914567033dc4,
title = "Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells.",
abstract = "Cilostazol, a type III phosphodiesterase inhibitor, is utilized for the treatment of intermittent claudication and is considered to have the beneficial effects against the atherogenic process. In the present study, we examined the effects of cilostazol on BH(4) biosynthesis in HUVEC treated with a mixture of the pro-inflammatory cytokines IFN-γ and TNF-α. Isolated HUVECs were grown to confluence and treated with IFN-γ (300 units/mL) and TNF-α (300 units/mL) for 16 h in order to stimulate BH(4) biosynthesis. The BH(4) levels were measured by HPLC. The mRNA expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme of BH(4) biosynthesis, and GTPCH feedback regulatory protein (GFRP) were quantified by real-time PCR. The GTPCH protein expression was assessed by western blot analysis. Cilostazol significantly reduced the BH(4) levels in cytokine-stimulated HUVEC. Cilostazol produced a concomitant increase in the cAMP levels in HUVEC. Cilostazol decreased the GTPCH activity as well as the expression of GTPCH mRNA and protein. 8-bromo-cAMP (8Br-cAMP), a cell-permeable cAMP analogue, did not reproduce the effects of cilostazol. Cilostazol did not affect the cytokine-induced inhibition of GFRP mRNA expression. We conclude that cilostazol inhibited cytokine-stimulated BH(4) biosynthesis via a cAMP-independent mechanism in HUVEC. Our data indicate that cilostazol reduced GTPCH activity and did so by suppressing the GTPCH protein levels.",
author = "Hiroaki Shiraishi and Kazuhisa Ikemoto and Shin Tada and Yasuhiro Udagawa and Masatsugu Ohtsuki and Chiho Sumi-Ichinose and Kazunao Kondo and Takahide Nomura",
year = "2011",
month = "4",
day = "27",
doi = "10.5551/jat.6361",
language = "English",
volume = "18",
pages = "312--317",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "4",

}

Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells. / Shiraishi, Hiroaki; Ikemoto, Kazuhisa; Tada, Shin; Udagawa, Yasuhiro; Ohtsuki, Masatsugu; Sumi-Ichinose, Chiho; Kondo, Kazunao; Nomura, Takahide.

In: Journal of atherosclerosis and thrombosis, Vol. 18, No. 4, 27.04.2011, p. 312-317.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells.

AU - Shiraishi, Hiroaki

AU - Ikemoto, Kazuhisa

AU - Tada, Shin

AU - Udagawa, Yasuhiro

AU - Ohtsuki, Masatsugu

AU - Sumi-Ichinose, Chiho

AU - Kondo, Kazunao

AU - Nomura, Takahide

PY - 2011/4/27

Y1 - 2011/4/27

N2 - Cilostazol, a type III phosphodiesterase inhibitor, is utilized for the treatment of intermittent claudication and is considered to have the beneficial effects against the atherogenic process. In the present study, we examined the effects of cilostazol on BH(4) biosynthesis in HUVEC treated with a mixture of the pro-inflammatory cytokines IFN-γ and TNF-α. Isolated HUVECs were grown to confluence and treated with IFN-γ (300 units/mL) and TNF-α (300 units/mL) for 16 h in order to stimulate BH(4) biosynthesis. The BH(4) levels were measured by HPLC. The mRNA expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme of BH(4) biosynthesis, and GTPCH feedback regulatory protein (GFRP) were quantified by real-time PCR. The GTPCH protein expression was assessed by western blot analysis. Cilostazol significantly reduced the BH(4) levels in cytokine-stimulated HUVEC. Cilostazol produced a concomitant increase in the cAMP levels in HUVEC. Cilostazol decreased the GTPCH activity as well as the expression of GTPCH mRNA and protein. 8-bromo-cAMP (8Br-cAMP), a cell-permeable cAMP analogue, did not reproduce the effects of cilostazol. Cilostazol did not affect the cytokine-induced inhibition of GFRP mRNA expression. We conclude that cilostazol inhibited cytokine-stimulated BH(4) biosynthesis via a cAMP-independent mechanism in HUVEC. Our data indicate that cilostazol reduced GTPCH activity and did so by suppressing the GTPCH protein levels.

AB - Cilostazol, a type III phosphodiesterase inhibitor, is utilized for the treatment of intermittent claudication and is considered to have the beneficial effects against the atherogenic process. In the present study, we examined the effects of cilostazol on BH(4) biosynthesis in HUVEC treated with a mixture of the pro-inflammatory cytokines IFN-γ and TNF-α. Isolated HUVECs were grown to confluence and treated with IFN-γ (300 units/mL) and TNF-α (300 units/mL) for 16 h in order to stimulate BH(4) biosynthesis. The BH(4) levels were measured by HPLC. The mRNA expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme of BH(4) biosynthesis, and GTPCH feedback regulatory protein (GFRP) were quantified by real-time PCR. The GTPCH protein expression was assessed by western blot analysis. Cilostazol significantly reduced the BH(4) levels in cytokine-stimulated HUVEC. Cilostazol produced a concomitant increase in the cAMP levels in HUVEC. Cilostazol decreased the GTPCH activity as well as the expression of GTPCH mRNA and protein. 8-bromo-cAMP (8Br-cAMP), a cell-permeable cAMP analogue, did not reproduce the effects of cilostazol. Cilostazol did not affect the cytokine-induced inhibition of GFRP mRNA expression. We conclude that cilostazol inhibited cytokine-stimulated BH(4) biosynthesis via a cAMP-independent mechanism in HUVEC. Our data indicate that cilostazol reduced GTPCH activity and did so by suppressing the GTPCH protein levels.

UR - http://www.scopus.com/inward/record.url?scp=80053631221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053631221&partnerID=8YFLogxK

U2 - 10.5551/jat.6361

DO - 10.5551/jat.6361

M3 - Article

C2 - 21224523

AN - SCOPUS:80053631221

VL - 18

SP - 312

EP - 317

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 4

ER -